




RESEARCH REPORT MARCH 2019



Immuno-Oncology Diagnostics

The Race for Biomarkers

Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis.

2019 to 2023



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Market Guides 14
 - iA. Situation Analysis..... 15
 - iB. Guide for Executives and Marketing Staff 17
 - iC. Guide for Investment Analysts and Management Consultants 18
 - iD. Impact of the Nobel Prize 19
- 1. Introduction and Market Definition 20
 - 1.1 What are Immuno-Oncology Diagnostics? 21
 - 1.2 Immuno-oncology – the looming cure..... 22
 - 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role 24
 - 1.3 Market Definition..... 24
 - 1.3.1 Market Size..... 25
 - 1.3.2 Currency 25
 - 1.3.3 Years 25
 - 1.4 Methodology..... 26
 - 1.4.1 Authors..... 26
 - 1.4.2 Sources 26
 - 1.5 U.S. Medical Market and laboratory Testing - Perspective 26
 - 1.4.1 U.S. Medicare Expenditures for Laboratory Testing 27
- 2. Immunotherapy – Guide to Immune Technologies 29
 - 2.0 The Immune System 30
 - 2.0.1 Innate immune system..... 31
 - 2.0.1.1 Surface barriers 31
 - 2.0.1.2 Inflammation 32
 - 2.0.1.3 Complement system..... 33

- 2.0.1.4 Cellular barriers 33
- 2.0.1.5 Natural killer cells 34
- 2.0.2 Adaptive immune system..... 35
 - 2.0.2.1 Lymphocytes..... 35
 - 2.0.2.2 Killer T cells 35
 - 2.0.2.3 Helper T cells 37
 - 2.0.2.4 Gamma delta T cells 38
 - 2.0.2.5 B lymphocytes and antibodies 38
- 2.0.3 Tumor immunology – the immune surveillance system 40
- 2.1 Immuno OncologyDiagnostics 42
 - 2.1.1 Checkpoint Assays 42
 - 2.1.1.1 Outlook for Checkpoint Assays..... 46
 - 2.1.2 Cytokine Assays 46
 - 2.1.2.1 Outlook for Cytokine Assays..... 47
 - 2.1.3 Genomic Germline 47
 - 2.1.3.1 Outlook for Genomic Germline 48
 - 2.1.4 Genomic Tumour..... 48
 - 2.1.4.1 Outlook for Genomic Tumour 50
 - 2.1.5 Tumor Microenviroment..... 51
 - 2.1.5.1 Outlook for Tumor Micro Environment 52
 - 2.1.6 Others..... 52
 - 2.1.6.1 Outlook for Other Diagnostics..... 52
- 3. Industry Overview 53
 - 3.1 Players in a Dynamic Market 54
 - 3.1.1 Academic Research Lab..... 54
 - 3.1.2 Diagnostic Test Developer..... 55
 - 3.1.3 Genomic Instrumentation Supplier..... 55

- 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier 55
- 3.1.4 Pharmaceutical/Reagent Supplier..... 55
- 3.1.5 Independent Testing Lab..... 55
- 3.1.6 Public National/regional lab..... 56
- 3.1.7 Hospital lab..... 56
- 3.1.8 Physician Lab 56
- 3.1.9 Audit Body 56
- 3.1.10 Certification Body..... 57
- 4. Market Trends 58
 - 4.1 Factors Driving Growth 59
 - 4.1.1 Outcome potential 59
 - 4.1.2 Companion Diagnostics..... 60
 - 4.1.3 Funding..... 60
 - 4.1.4 Technology Environment 60
 - 4.1.5 Target Solutions 61
 - 4.2 Factors Limiting Growth..... 62
 - 4.2.1 Complex Role of Diagnostics 62
 - 4.2.2 Clinical Trials Role..... 63
 - 4.2.3 Protocols..... 63
 - 4.3 Diagnostic Technology Development 64
 - 4.3.1 Combinations - Issues and Complexity 64
 - 4.3.2 Shifting Role of Diagnostics 65
 - 4.3.3 Multiplexing and Foundation One 66
 - 4.3.4 The Disruption Dynamic 66
 - 4.3.5 The Race for Biomarkers 67
 - 4.3.6 The Next Five Years 68
- 5. Cancer Immunotherapy Recent Developments 69

5.1 Recent Developments – Importance and How to Use This Section	70
5.1.1 Importance of These Developments.....	70
5.1.2 How to Use This Section.....	70
Icon Acquires MolecularMD	70
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca.....	71
Tumor Mutational Burden as Predictor of Immunotherapy Success	72
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda.....	74
Abcam Acquires Calico Biolabs	75
Cancer Genetics and NovellusDx to Merge	76
ApoCell Expands Immuno-Oncology Biomarker Services.....	77
MRM Proteomics Inc and Exactis Innovation Partner	79
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma.....	80
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution	81
MolecularMD Launches Validated Tumor Mutation Burden Assay	82
Minomic Secures Key Patent in the United States and China	83
Biocartis and Wondfo Announce Joint Venture	84
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics	84
Cancer Genetics Expands Immuno-Oncology Panel	85
10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product.....	87
Qiagen, Freenome Partner to Improve Companion Diagnostic Development.....	88
Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime	88
Thermo Fisher Expands OncoPrint Immuno-Oncology Assay Portfolio	90
Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies.....	90
HalioDx announces high capacity IHC multiplex technology.....	91
MolecularMD to Implement Promega’s Technology.....	92
NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel	93
MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response	94

Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC	96
HaliuDx Closes €18.5M Series B Round	96
Announcement of the 2018 Nobel Prize in Physiology or Medicine	97
6. Profiles of Key Immunotherapy Companies	100
10X Genomics	101
Abbott Laboratories	102
Abcam	104
Adaptive Biotechnologies	105
Aethlon Medical	106
Agena Bioscience	107
Angle plc	109
Apocell	110
ARUP Laboratories	111
Beckman Coulter	113
Becton Dickinson	114
Bioarray Genetics	116
BioCartis	117
Biocept	118
Biodesix Inc.	119
BioFluidica	120
BioGenex	121
bioMérieux	122
Bio-Rad	123
Bio-Techne	124
Bristol-Myers Squibb	125
Cancer Genetics	126
Caris Molecular Diagnostics	127

CellMax Life.....	128
Charles River	129
Chronix Biomedical	130
Circulogene	131
Clearbridge BioMedics	132
Clinical Genomics	133
Cynvenio	134
Cytolumina Technologies Corp.	135
CytoTrack	136
Dako (Agilent)	137
Diagnologix LLC.....	139
Epic Sciences	140
Exosome Diagnostics	141
Fluidigm Corp.....	142
Fluxion Biosciences	143
Foundation Medicine.....	144
Freenome.....	145
Genomic Health	146
GenomOncology	147
GRAIL.....	148
Guardant Health	149
HalioDx.....	150
Horizon Discovery	151
HTG Molecular Diagnostics.....	152
iCellate.....	154
Illumina	155
Incell Dx.....	156

Inivata	157
Integrated Diagnostics	158
Invivoscribe	159
Leica Biosystems	160
Luminex.....	161
MDx Health	162
Merck & Co., Inc.....	163
MIODx	164
Molecular MD	165
MRM Proteomics Inc.....	166
Myriad Genetics/Myriad RBM	167
Nanostring.....	168
Natera	169
Neogenomics	170
New Oncology.....	171
Oncocyte	172
Ortho Clinical Diagnostics	173
Perkin Elmer.....	174
Personal Genome Diagnostics	175
Pfizer	176
Promega.....	178
Protagen Diagnostics	180
Qiagen.....	181
Quanterix	183
Rarecells SAS.....	184
Roche Diagnostics	185
Siemens.....	187

Silicon Biosystems	188
SkylineDx	189
SRI International	190
Sysmex	191
Thermo Fisher	192
Trovagene	194
Vortex Biosciences	195
7. Global Market Size	196
7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts	197
7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts	199
8. Global Market by Type	201
8.1 Checkpoint Assay Market	202
8.1.1 Checkpoint Assay Market by Country with Chart	202
8.2 Cytokine Assay Market	204
8.2.1 Cytokine Assay Market by Country with Chart	204
8.3 Genome Germline Market	206
8.3.1 Genome Germline Market by Country with Chart	206
8.4 Genome Tumour Market	208
8.4.1 Genome Tumour Market by Country with Chart	208
8.5 Tumour Micro Environment Market	210
8.5.1 Tumour Micro Environment Market by Country with Chart	210
8.6 Other Market	212
8.6.1 Other Market by Country with Chart	212
9. Appendices	214
9.1 FDA Cancer Drug Approvals by Year	215
9.2 Clinical Trials Started 2010 to 2016	216
9.3 Prevalence of Cancer Treatments – 2015	217

Table of Tables

Table 1 List of Cancers by Mortality 23

Table 2 Lab Spending 2014 to 2024 28

Table 3 Overview of Innate and Adaptive Immunity..... 31

Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment 43

Table 5 FDA Approved Companion diagnostics in Cancer treatment 48

Table 6 Market Players by Type..... 54

Table 7 Five Factors Driving Growth..... 59

Table 8 Three Factors Limiting Growth 62

Table 9 Immuno-oncology Diagnostics Global Market by Country/Region 197

Table 10 Immuno-oncology Diagnostics Global Market by Type..... 199

Table 11 Checkpoint Assay Market by Country..... 202

Table 12 Cytokine Assay Market by Country..... 204

Table 13 Genome Germline Market by Country 206

Table 14 Genome Tumour Market by Country 208

Table 15 Tumour Micro Environment Market by Country 210

Table 16 Other Market by Country 212

Table of Figures

Figure 1 Cancer Death Rates – USA, CDC 22

Figure 2 Clinical Lab Spending 2014 to 2024 27

Figure 3 Helper T Cell Roles 37

Figure 4 Antibody Diagram 39

Figure 5 Macrophages attack a Cancer Cell 40

Figure 6 The Tumour Micro Environment 51

Figure 7 Comparing IO Diagnostic and Traditional Testing 65

Figure 8 Growth rates of IO Diagnostic Technologies 68

Figure 9 Market Size by Country - Key Countries 198

Figure 10 Global Market by Country 198

Figure 11 Chart of Global Market by Type 199

Figure 12 Growth Rates of Diagnostic Segments 200

Figure 13 IO Diagnostics Share Change by Type 200

Figure 14 Chart – Checkpoint Assay Market by Country 203

Figure 15 Chart – Cytokine Assay Market by Country 205

Figure 16 Chart – Genome Germline Market by Country 207

Figure 17 Chart - Genome Tumour Market by Country 209

Figure 18 Chart – Tumour Micro Environment Market by Country 211

Figure 19 Chart – Other Market, Global Size 213

Figure 20 FDA Cancer Drug Approvals by Year 215

Figure 21 Clinical Trials for Immunotherapy by Year 216

Figure 22 Pie Chart of Prevalence of Cancer Treatments 217